Triple immune checkpoint blockade induces immune-mediated cardiomyocyte injury: translational implications for cardio-oncology surveillance
Clicks: 1
ID: 323283
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #220 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Immune checkpoint inhibitors (ICIs) have transformed cancer care, yet immune-related adverse events involving the cardiovascular system—particularly myocarditis—remain among the most severe and life-threatening complications. While dual ICI regimens are known to increase cardiotoxic risk, the cardiovascular safety profile of emerging triple ICI combinations remains largely undefined. As multi-agent immune checkpoint blockade expands in clinical development, understanding its potential to trigger immune-mediated cardiac injury has become a critical unmet need in cardio-oncology. Methods A translational co-culture model combining human induced pluripotent stem cell–derived cardiomyocytes and human peripheral blood mononuclear cells was established to evaluate immune-driven cardiotoxicity. Cultures were exposed for 48 hours to immune checkpoint blockade with nivolumab plus relatlimab, ipilimumab, or atezolizumab, administered as monotherapies, doublets, or triplet combinations. Cardiomyocyte injury was quantified by lactate dehydrogenase release. Immune activation was assessed by measurement of IL-2, granzyme B, and pro-inflammatory cytokines, including components of the NLRP3 inflammasome pathway. Digital microscopy was used to evaluate immune–cardiomyocyte interactions and structural integrity. Results Triple immune checkpoint blockade induced a marked increase in cardiomyocyte injury compared with single-agent or dual ICI exposure (p < 0.001). This cytotoxic effect was associated with robust immune activation, characterised by elevated IL-2 and granzyme B secretion and amplification of pro-inflammatory and inflammasome-related signalling. Morphological analyses confirmed pronounced immune cell activation and a significant reduction in cardiomyocyte density following triplet exposure. In contrast, single and dual ICI regimens elicited comparatively limited cardiomyocyte damage. Conclusions These data provide the first preclinical evidence that triple immune checkpoint blockade can directly promote immune-mediated cardiomyocyte injury through exaggerated inflammatory and cytotoxic immune responses. The findings raise a translational alert for cardio-oncology, underscoring the need for intensified cardiovascular monitoring and immune-related cardiotoxicity surveillance in patients receiving multi-agent ICI regimens. As triplet immune checkpoint strategies advance toward clinical application, proactive integration of cardio-oncology expertise will be essential to mitigate cardiovascular risk without compromising oncological efficacy.
| Reference Key |
openalex_W7172268820
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | N Maurea, M Passariello, M Belardo, A Esposito, M Paone, M Berretta, R Arianna, A Paccone, F Maurea, M L Canale, C Cadeddu Dessalvi, C De Lorenzo, S Oliva, G Novo, V Quagliariello |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.007
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.